I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
DataSheet1_The cost-effectiveness of cemiplimab plus chemot..:
Tingting Lu
;
Yufan Huang
;
Zhongjie Cai
...
doi:10.3389/fphar.2023.1171302.s001. , 2023
Link:
https://doi.org/10.3389/fphar.2023.1171302.s001
RT Journal T1
DataSheet1_The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.docx
UL https://suche.suub.uni-bremen.de/peid=base-ftfrontimediafig:oai:figshare.com:article_23752272&Exemplar=1&LAN=DE A1 Tingting Lu A1 Yufan Huang A1 Zhongjie Cai A1 Wangchun Lin A1 Xiaoxiao Chen A1 Ruijia Chen A1 Yingying Hu YR 2023 K1 Pharmacology K1 Basic Pharmacology K1 Clinical Pharmacology and Therapeutics K1 Clinical Pharmacy and Pharmacy Practice K1 Pharmaceutical Sciences K1 Pharmacogenomics K1 Toxicology (incl. Clinical Toxicology) K1 Pharmacology and Pharmaceutical Sciences not elsewhere classified K1 cost-effectiveness K1 cemiplimab K1 chemotherapy K1 advanced non-small cell lung cancer K1 first-line treatment JF doi:10.3389/fphar.2023.1171302.s001 LK http://dx.doi.org/https://doi.org/10.3389/fphar.2023.1171302.s001 DO https://doi.org/10.3389/fphar.2023.1171302.s001 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)